Skip to main content
. 2023 Sep 30;9:79. doi: 10.1038/s41523-023-00586-3

Table 2.

Patient and tumor characteristics at the time of first RS and second RS testing in the study cohort.

First BC n = 60 Second BC n = 60 p*
Median (IQR) age at testing, years 55.5 (44–62) 60.5 (50–67) <0.001
Median (IQR) tumor size, cm 1.6 (1.1–2.2) 1.4 (1.0–1.8) 0.54
Tumor size category, n (%) 0.096a
≤1 cm 15 (25.0%) 16 (26.7%)
>1-2 cm 27 (45.0%) 32 (53.3%)
>2 cm 18 (30.0%) 9 (15.0%)
Not available 0 (0%) 3 (5.0)
Tumor grade category, n (%) 0.79b
Grade 1 9 (15.0%) 6 (10.0%)
Grade 2 32 (53.3%) 36 (60.0%)
Grade 3 10 (16.7%) 9 (15.0%)
Not available 9 (15.0%) 9 (15.0%)
Histology, n (%) 0.75c
IDC 50 (83.3%) 48 (80.0%)
ILC 5 (8.3%) 10 (16.7%)
Mucinous/colloid/papillary 2 (3.3%) 1 (1.7%)
Other/not available 3 (5.0%) 1 (1.7%)
Nodal status, n (%) 0.21d
N0 46 (76.7%) 49 (81.7%)
N1mi 8 (13.3%) 1 (1.7%)
N1 6 (10.0%) 7 (11.7%)
Not available 0 (0.0%) 3 (5.0%)

BC breast cancer, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, IQR interquartile range.

*p value for Wilcoxon signed-rank test and the McNemar’s test for continuous and categorical variables, respectively. Bolded p values are statistically significant. McNemar’s test contingency tables are presented in Supplementary Table 1.

aFor comparing tumor size ≥2 cm to <2 cm.

bFor comparing grade 1/2 to grade 3.

cFor comparing IDC to non-IDC histologies.

dFor comparing N0 to N1/N1mi patients.